Sat, May 25, 2013, 12:24 PM EDT - U.S. Markets closed
Priority review granted by the FDA for TTNP's 6 month implant to treat drug addiction.
Millions are hooked on pain meds and illicit drugs.
Approval on April 30 will earn TTNP a $50 million milestone plus hefty double digit royalties.
TTNP is also advancing its ProNeura technology for chronic pain and Parkinson's.
Load'em up, mov'em out.
Now that's a stock!!!!!!
Huge network coverage on April approval.
This will be bigger than big.
Yep, UP again!!!!